Bedaquiline, Delamanid, Moxifloxacin

DRUG2 trials

Sponsors

Michael Hoelscher, LigaChem Biosciences, Inc.

Conditions

Infections and InfestationsOther Specified Pulmonary TuberculosisPulmonary Tuberculosis

Phase 2

PanACEA Sutezolid Dose-finding and Combination Evaluation

CompletedNCT03959566

Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculosis

Start: 2021-05-06End: 2022-09-30Updated: 2023-05-01

PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)

CompletedNCT04550832

LigaChem Biosciences, Inc.Infections and Infestations, Pulmonary Tuberculosis

Start: 2021-10-28End: 2023-09-11Updated: 2025-09-16

Related Papers

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

2025-07-085 citations

Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.

2025-07-084 citations

Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic.

2024-12-18

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.

2023-06-0611 citations